David A. Siegel Genprex, Inc. Transaction History

Two Sigma Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $14,080 - $25,410	-11,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $14,196 - $27,300	-7,800 Reduced 41.49%	11,000 $25,000
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $22,748 - $50,760	18,800 New	18,800 $25,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $90.3M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.